NCT00699283 - A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Epilepsy

Interventions

DRUG

Brivaracetam

25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)

DRUG

Brivaracetam

25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)

Trial Locations (68)

Unknown

Little Rock

Garden Grove

Loma Linda

Newport Beach

Riverside

Sacramento

Stanford

Denver

Fort Collins

Danbury

New Haven

Waterbury

Gainesville

Miami

Atlanta

Honolulu

Chicago

Danville

Elkhart

Waldorf

Grand Rapids

Columbia

Lebanon

Albuquerque

Flushing

Schenectady

Charlotte

Oberlin

Westerville

Tulsa

Bethlehem

Jenkintown

Providence

Austin

Bedford

San Antonio

Layton

Ogden

Burlington

Bluefield

Seattle

Morgantown

Marshfield

Béthune

Lille

Saint-Brieuc

Toulouse

Berlin

Bernau

Bielefeld

München

Münster

Ulm

Budapest

Debrecen

Kecskemét

Szeged

Bergamo

Florence

Germaneto

Messina

Perugia

Pisa

Torino

Barcelona

Madrid

Murcia

Zaragoza